EP1097147A4 - Nouveaux inhibiteurs de l'angiogenese - Google Patents
Nouveaux inhibiteurs de l'angiogeneseInfo
- Publication number
- EP1097147A4 EP1097147A4 EP99937204A EP99937204A EP1097147A4 EP 1097147 A4 EP1097147 A4 EP 1097147A4 EP 99937204 A EP99937204 A EP 99937204A EP 99937204 A EP99937204 A EP 99937204A EP 1097147 A4 EP1097147 A4 EP 1097147A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- angiogenesis inhibitors
- novel angiogenesis
- novel
- inhibitors
- angiogenesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9228598P | 1998-07-10 | 1998-07-10 | |
| US92285P | 1998-07-10 | ||
| GBGB9822700.2A GB9822700D0 (en) | 1998-10-16 | 1998-10-16 | Novel angiogenesis inhibitors |
| GB9822700 | 1998-10-16 | ||
| PCT/US1999/015200 WO2000002871A1 (fr) | 1998-07-10 | 1999-07-06 | Nouveaux inhibiteurs de l'angiogenese |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1097147A1 EP1097147A1 (fr) | 2001-05-09 |
| EP1097147A4 true EP1097147A4 (fr) | 2001-11-21 |
Family
ID=26314531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP99937204A Withdrawn EP1097147A4 (fr) | 1998-07-10 | 1999-07-06 | Nouveaux inhibiteurs de l'angiogenese |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1097147A4 (fr) |
| JP (1) | JP2002520324A (fr) |
| AU (1) | AU747427B2 (fr) |
| CA (1) | CA2336848A1 (fr) |
| WO (1) | WO2000002871A1 (fr) |
Families Citing this family (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| NZ513639A (en) | 1999-04-15 | 2004-02-27 | Bristol Myers Squibb Co | Cyclic protein tyrosine kinase inhibitors |
| DE10021246A1 (de) * | 2000-04-25 | 2001-10-31 | Schering Ag | Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel |
| AU3113902A (en) | 2000-12-21 | 2002-07-01 | Bristol Myers Squibb Co | Thiazolyl inhibitors of tec family tyrosine kinases |
| ES2556946T3 (es) | 2000-12-21 | 2016-01-21 | Novartis Ag | Pirimidinaminas como moduladores de la angiogénesis |
| US7081454B2 (en) | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
| US6693134B2 (en) | 2001-05-29 | 2004-02-17 | Chemokine Therapeutics Corporation | Bicyclic aromatic chemokine receptor ligands |
| US7265134B2 (en) | 2001-08-17 | 2007-09-04 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| EP1503757B1 (fr) | 2002-05-02 | 2007-12-19 | Merck & Co., Inc. | Inhibiteurs de la tyrosine kinase |
| JP4896518B2 (ja) * | 2002-12-13 | 2012-03-14 | ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド | ニコチンアミド系キナーゼ阻害薬 |
| NZ544797A (en) | 2003-07-18 | 2011-04-29 | Amgen Fremont Inc | Specific antibodies that bind HGF and neutralise binding of HGF to met |
| US7312215B2 (en) | 2003-07-29 | 2007-12-25 | Bristol-Myers Squibb Company | Benzimidazole C-2 heterocycles as kinase inhibitors |
| ES2611604T3 (es) * | 2004-10-22 | 2017-05-09 | Janssen Pharmaceutica Nv | Inhibidores de la c fms quinasa |
| US7652009B2 (en) | 2004-11-30 | 2010-01-26 | Amgem Inc. | Substituted heterocycles and methods of use |
| US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
| US20080108664A1 (en) | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
| AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| ATE489380T1 (de) | 2006-02-10 | 2010-12-15 | Amgen Inc | Hydratformen von amg706 |
| US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
| EP2016070B1 (fr) | 2006-04-20 | 2016-01-13 | Janssen Pharmaceutica N.V. | Inhibiteurs de la c-fms kinase |
| MX2008013533A (es) | 2006-04-20 | 2009-01-15 | Janssen Pharmaceutica Nv | Compuestos heterociclicos como inhibidores de c-fms cinasa. |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| WO2008079291A2 (fr) | 2006-12-20 | 2008-07-03 | Amgen Inc. | Hétérocycles substitués et leurs méthodes d'utilisation |
| WO2008086014A2 (fr) | 2007-01-09 | 2008-07-17 | Amgen Inc. | Dérivés de bis-aryl amide et procédés d'utilisation |
| GB0701426D0 (en) * | 2007-01-25 | 2007-03-07 | Univ Sheffield | Compounds and their use |
| US8314087B2 (en) | 2007-02-16 | 2012-11-20 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and methods of use |
| RS56743B1 (sr) | 2007-08-21 | 2018-03-30 | Amgen Inc | Humani c-fms antigen vezujući proteini |
| JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
| US9029411B2 (en) | 2008-01-25 | 2015-05-12 | Millennium Pharmaceuticals, Inc. | Thiophenes and uses thereof |
| EP2107054A1 (fr) * | 2008-04-01 | 2009-10-07 | Università Degli Studi Di Milano - Bicocca | Composés antiprolifératives et ses utilisations thérapeutiques |
| US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
| US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| US9139589B2 (en) | 2009-01-30 | 2015-09-22 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| WO2011161217A2 (fr) | 2010-06-23 | 2011-12-29 | Palacký University in Olomouc | Ciblage du vegfr2 |
| WO2012021611A1 (fr) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Hétéroaryles et utilisations de ceux-ci |
| MA34797B1 (fr) | 2010-08-11 | 2014-01-02 | Millennium Pharm Inc | Hétéroaryles et leurs utilisations |
| EP2603216A4 (fr) * | 2010-08-11 | 2013-12-18 | Millennium Pharm Inc | Hétéroaryles et utilisations |
| WO2012051410A2 (fr) | 2010-10-13 | 2012-04-19 | Millennium Pharmaceuticals, Inc. | Hétéroaryles et utilisations de ceux-ci |
| DK2937349T3 (en) | 2011-03-23 | 2017-02-20 | Amgen Inc | CONDENSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 |
| CA2831966C (fr) | 2011-05-23 | 2016-07-19 | Merck Patent Gmbh | Derives de thiazole |
| US9745288B2 (en) | 2011-08-16 | 2017-08-29 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| CN104870454B (zh) | 2012-08-07 | 2020-03-03 | 詹森药业有限公司 | 用于制备杂环酯衍生物的方法 |
| CN107266405A (zh) | 2012-08-07 | 2017-10-20 | 詹森药业有限公司 | 用于制备c‑fms激酶抑制剂的方法 |
| EP2890696A1 (fr) | 2012-08-29 | 2015-07-08 | Amgen, Inc. | Composés quinazolinones et leurs dérivés |
| CN104860885B (zh) * | 2014-02-24 | 2017-11-17 | 中国科学院上海药物研究所 | 萘酰胺类化合物、其制备方法和用途 |
| AU2016205311B2 (en) | 2015-01-08 | 2022-02-17 | The Board Of Trustees Of The Leland Stanford Junior University | Factors and cells that provide for induction of bone, bone marrow, and cartilage |
| WO2016202935A1 (fr) | 2015-06-19 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Inhibiteurs de transport du glucose |
| CA3048217A1 (fr) | 2016-12-22 | 2018-06-28 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procedes d'utilisation |
| ES2905676T3 (es) | 2017-05-22 | 2022-04-11 | Amgen Inc | Inhibidores de KRAS G12C y métodos para su uso |
| CN111051306B (zh) | 2017-09-08 | 2023-01-03 | 美国安进公司 | Kras g12c的抑制剂及其使用方法 |
| ES2995514T3 (en) | 2018-05-04 | 2025-02-10 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
| MX2020010836A (es) | 2018-05-04 | 2021-01-08 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso. |
| EP3790886B1 (fr) | 2018-05-10 | 2024-06-26 | Amgen Inc. | Inhibiteurs du kras g12c pour le traitement du cancer |
| AU2019278998B2 (en) | 2018-06-01 | 2023-11-09 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| MX2020012204A (es) | 2018-06-11 | 2021-03-31 | Amgen Inc | Inhibidores de kras g12c para tratar el cáncer. |
| CA3100390A1 (fr) | 2018-06-12 | 2020-03-12 | Amgen Inc. | Inhibiteurs de kras g12c regroupant un cycle de piperazine et utilisation dans le traitement du cancer |
| JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法 |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| CA3117222A1 (fr) | 2018-11-19 | 2020-05-28 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procedes d'utilisation |
| WO2020132651A1 (fr) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Inhibiteurs de kif18a |
| PE20211475A1 (es) | 2018-12-20 | 2021-08-05 | Amgen Inc | Inhibidores de kif18a |
| MX2021007157A (es) | 2018-12-20 | 2021-08-16 | Amgen Inc | Heteroarilamidas utiles como inhibidores de kif18a. |
| CA3123227A1 (fr) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Amides d'heteroaryle utiles en tant qu'inhibiteurs de kif18a |
| JP2022522777A (ja) | 2019-03-01 | 2022-04-20 | レボリューション メディシンズ インコーポレイテッド | 二環式ヘテロアリール化合物及びその使用 |
| EP3930845A1 (fr) | 2019-03-01 | 2022-01-05 | Revolution Medicines, Inc. | Composés hétérocyclyle bicycliques et leurs utilisations |
| EP3738593A1 (fr) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosage d'inhibiteur de kras pour le traitement de cancers |
| CN114144414B (zh) | 2019-05-21 | 2025-11-07 | 美国安进公司 | 固态形式 |
| US12540129B2 (en) | 2019-08-02 | 2026-02-03 | Amgen Inc. | KIF18A inhibitors |
| WO2021026101A1 (fr) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Inhibiteurs de kif18a |
| CA3147272A1 (fr) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Inhibiteurs de kif18a |
| CN114302880B (zh) | 2019-08-02 | 2025-07-15 | 美国安进公司 | Kif18a抑制剂 |
| MX2022004656A (es) | 2019-10-24 | 2022-05-25 | Amgen Inc | Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer. |
| CN114867735A (zh) | 2019-11-04 | 2022-08-05 | 锐新医药公司 | Ras抑制剂 |
| PE20221277A1 (es) | 2019-11-04 | 2022-09-05 | Revolution Medicines Inc | Inhibidores de ras |
| CN114786777A (zh) | 2019-11-04 | 2022-07-22 | 锐新医药公司 | Ras抑制剂 |
| PE20230249A1 (es) | 2019-11-08 | 2023-02-07 | Revolution Medicines Inc | Compuestos de heteroarilo biciclicos y usos de estos |
| TW202132271A (zh) | 2019-11-14 | 2021-09-01 | 美商安進公司 | Ｋｒａｓ ｇ１２ｃ抑制劑化合物之改善的合成 |
| CA3158188A1 (fr) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Synthese amelioree de compose inhibiteur de kras g12c |
| EP4065231A1 (fr) | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Inhibiteurs de ras covalents et leurs utilisations |
| CA3163703A1 (fr) | 2020-01-07 | 2021-07-15 | Steve Kelsey | Dosage d'inhibiteurs de shp2 et methodes de traitement du cancer |
| KR20230042600A (ko) | 2020-06-18 | 2023-03-28 | 레볼루션 메디슨즈, 인크. | Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법 |
| CA3187757A1 (fr) | 2020-09-03 | 2022-03-24 | Ethan AHLER | Utilisation d'inhibiteurs de sos1 pour traiter des malignites a mutations de shp2 |
| AU2021345111B2 (en) | 2020-09-15 | 2025-11-27 | Revolution Medicines, Inc. | Indole derivatives as Ras inhibitors in the treatment of cancer |
| EP4267250A1 (fr) | 2020-12-22 | 2023-11-01 | Qilu Regor Therapeutics Inc. | Inhibiteurs de sos1 et utilisations associées |
| EP4334324A1 (fr) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Inhibiteurs de ras covalents et leurs utilisations |
| CR20230558A (es) | 2021-05-05 | 2024-01-24 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cáncer |
| AR125782A1 (es) | 2021-05-05 | 2023-08-16 | Revolution Medicines Inc | Inhibidores de ras |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| WO2023114954A1 (fr) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Composés pyrazolopyrazine utilisés comme inhibiteurs de la shp2 |
| EP4227307A1 (fr) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Composés pyrazolopyrazine en tant qu'inhibiteurs de shp2 |
| IL314883A (en) | 2022-03-07 | 2024-10-01 | Amgen Inc | Process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile |
| WO2023172940A1 (fr) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Méthodes de traitement du cancer du poumon réfractaire immunitaire |
| AU2023285116A1 (en) | 2022-06-10 | 2024-12-19 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| EP4601644A1 (fr) | 2022-10-14 | 2025-08-20 | Black Diamond Therapeutics, Inc. | Méthodes de traitement de cancers à l'aide de dérivés d'isoquinoline ou de 6-aza-quinoléine |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024211663A1 (fr) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Composés macrocycliques condensés en tant qu'inhibiteurs de ras |
| EP4688790A1 (fr) | 2023-04-07 | 2026-02-11 | Revolution Medicines, Inc. | Composés macrocycliques condensés en tant qu'inhibiteurs de ras |
| AU2024252105A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| WO2024216016A1 (fr) | 2023-04-14 | 2024-10-17 | Revolution Medicines, Inc. | Formes cristallines d'un inhibiteur de ras |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025137507A1 (fr) | 2023-12-22 | 2025-06-26 | Regor Pharmaceuticals, Inc. | Inhibiteurs de sos1 et leurs utilisations |
| WO2025171296A1 (fr) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2025240847A1 (fr) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2025255438A1 (fr) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras |
| WO2025265060A1 (fr) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Compositions thérapeutiques et procédés de gestion d'effets liés au traitement |
| WO2026006747A1 (fr) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026015801A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble liés à ras |
| WO2026015790A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble lié à ras |
| WO2026015796A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble lié à ras |
| WO2026015825A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas |
| WO2026050446A1 (fr) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026072904A2 (fr) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions et méthodes de traitement du cancer du poumon |
| WO2026090116A2 (fr) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026090245A1 (fr) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Utilisation d'inhibiteurs ras pour traiter un cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5104889A (en) * | 1986-08-04 | 1992-04-14 | Otsuka Pharmaceutical Factory, Inc. | Thiazole derivatives |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1497536A (en) * | 1973-12-17 | 1978-01-12 | Lilly Industries Ltd | 2-acylaminooxazoles methods for their preparation and their use |
| DE3864248D1 (de) * | 1987-12-14 | 1991-09-19 | Sawai Seiyaku Kk | Carboxamide mit tetrazol- und thiazol-ringen und ihre anwendung. |
-
1999
- 1999-07-06 CA CA002336848A patent/CA2336848A1/fr not_active Abandoned
- 1999-07-06 WO PCT/US1999/015200 patent/WO2000002871A1/fr not_active Ceased
- 1999-07-06 AU AU52082/99A patent/AU747427B2/en not_active Ceased
- 1999-07-06 EP EP99937204A patent/EP1097147A4/fr not_active Withdrawn
- 1999-07-06 JP JP2000559102A patent/JP2002520324A/ja not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5104889A (en) * | 1986-08-04 | 1992-04-14 | Otsuka Pharmaceutical Factory, Inc. | Thiazole derivatives |
Non-Patent Citations (5)
| Title |
|---|
| CHEM. HETEROCYCL. COMPD. (ENGL. TRANSL.) (1974), 10(7), 928-931 * |
| DATABASE BEILSTEIN [online] BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT/MAIN, DE; XP002176558, Database accession no. 998965 (BRN) * |
| DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002176557, retrieved from STN Database accession no. 75:35847 * |
| See also references of WO0002871A1 * |
| YAKUGAKU ZASSHI (1971), 91(4), 436-443 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU5208299A (en) | 2000-02-01 |
| AU747427B2 (en) | 2002-05-16 |
| CA2336848A1 (fr) | 2000-01-20 |
| JP2002520324A (ja) | 2002-07-09 |
| WO2000002871A1 (fr) | 2000-01-20 |
| EP1097147A1 (fr) | 2001-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB9900416D0 (en) | Inhibitors | |
| PL341642A1 (en) | Novel macrolydes | |
| ZA98376B (en) | Sulfamide-metalloprotease inhibitors | |
| GB2321641B (en) | Sulfamide-metalloprotease inhibitors | |
| HUP0202076A3 (en) | Triazine angiogenesis inhibitors | |
| EP1068213A4 (fr) | Nouveaux siloxanes amino-organo-fonctionnels | |
| PL345574A1 (en) | Angiogenesis inhibitors | |
| GB9821993D0 (en) | Centraliser | |
| EP1153022A4 (fr) | Inhibiteurs de protease | |
| GB9816729D0 (en) | Substituted cyclohexylaminopyrimidines | |
| PL347397A1 (en) | Substituted 3-aryl-pyrazoles | |
| GB9817029D0 (en) | Novel compounds | |
| GB2389113B (en) | B-secretase inhibitor | |
| HUP0103576A3 (en) | Kdel receptor inhibitors | |
| HUP0102476A3 (en) | Substituted cyclooctadepsipeptides | |
| GB9810544D0 (en) | Novel angiogenesis inhibitors | |
| GB9822700D0 (en) | Novel angiogenesis inhibitors | |
| GB9800681D0 (en) | Novel angiogenesis inhibitors | |
| TW407677U (en) | Form | |
| GB9803416D0 (en) | Inhibitors | |
| GB9828697D0 (en) | Inhibitors | |
| GB9826992D0 (en) | Inhibitors | |
| ZA9811227B (en) | Triazine angiogenesis inhibitors | |
| SI1037886T1 (en) | Triazine angiogenesis inhibitors | |
| GB9825756D0 (en) | Novel compoundd |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20010212 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
| RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7C 07D 263/48 A, 7C 07D 277/46 B, 7A 61K 31/42 B, 7A 61K 31/425 B, 7C 07D 413/04 B, 7C 07D 413/14 B |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20011005 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| 17Q | First examination report despatched |
Effective date: 20030918 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20040330 |